Allgulander S, Holm S, Lundgren C
Infection. 1979;7 Suppl 4:S404-7. doi: 10.1007/BF01639022.
In a double-blind study geriatric patients received either 410 mg sulphadiazine plus 90 mg trimethoprim (co-trimazine) or 800 mg sulphamethoxazole plus 160 mg trimethoprim (co-trimoxazole) twice daily. The investigation was carried out in order to compare the clinical efficacy and safety of co-trimazine in relation to co-trimoxazole with special emphasis on laboratory data in elderly patients suffering from uncomplicated urinary tract infections. Two to four weeks after start of treatment the original pathogen was eradicated in 80% of the 40 patients that were assessable for the effect of co-trimazine therapy, and in 77.8% of the 39 assessable patients in the co-trimoxazole group. There were no statistically significant differences between the two treatment groups in terms of laboratory data. Both drugs were well tolerated.
在一项双盲研究中，老年患者每日两次服用410毫克磺胺嘧啶加90毫克甲氧苄啶（复方磺胺嘧啶）或800毫克磺胺甲恶唑加160毫克甲氧苄啶（复方新诺明）。开展该调查是为了比较复方磺胺嘧啶与复方新诺明的临床疗效和安全性，特别关注患有单纯性尿路感染的老年患者的实验室数据。治疗开始两到四周后，在可评估复方磺胺嘧啶治疗效果的40例患者中，80%的患者根除了原始病原体；在复方新诺明组的39例可评估患者中，这一比例为77.8%。两个治疗组在实验室数据方面无统计学显著差异。两种药物耐受性均良好。
